Prescription for Long-Term Value

PharmaFutures 2 built on the successful formula of PhamaFutures 1, which brought together industry and investors in structured dialogue. However, the approach to this second phase was to analyse the present operating environment rather than to focus on long-term futures. The overall findings by the people and partners involved in the project identified three trends that will determine the industry’s future value: R&D productivity, consensus on value for money and the emerging markets.

The process culminated in 2007 in the report PharmaFutures 2. The report reviews these trends, their social consequences and how industry and investors might address them to meet both shareholder and societal needs. The dialogue focused on how the industry communicates with investors and how investors in turn signal what they want to know.

Download

Download PharmaFutures 2

Comments

Innovation remains core to our success, ensuring we research and develop new medicines and vaccines which address unmet medical needs. The Shared Value report outlines how all stakeholders including industry, investors, governments and regulators can play their part in ensuring the appropriate balance between value for money and delivering fair rewards for innovation can be achieved.

Simon Jose, GSK